These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18852126)

  • 1. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.
    Sarup J; Jin P; Turin L; Bai X; Beryt M; Brdlik C; Higaki JN; Jorgensen B; Lau FW; Lindley P; Liu J; Ni I; Rozzelle J; Kumari R; Watson SA; Zhang J; Shepard HM
    Mol Cancer Ther; 2008 Oct; 7(10):3223-36. PubMed ID: 18852126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
    Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
    Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade.
    Gompels LL; Malik NM; Madden L; Jin P; Feldmann M; Shepard HM; Paleolog EM
    Arthritis Res Ther; 2011; 13(5):R161. PubMed ID: 21982514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
    Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
    Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
    Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
    Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
    Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
    Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.
    Gu J; Chen L; Shatos MA; Rios JD; Gulati A; Hodges RR; Dartt DA
    Exp Eye Res; 2008 Feb; 86(2):322-34. PubMed ID: 18155194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
    Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.
    Woisetschläger M; Antes B; Borrowdale R; Wiederkum S; Kainer M; Steinkellner H; Wozniak-Knopp G; Moulder K; Rüker F; Mudde GC
    Biotechnol J; 2014 Jun; 9(6):844-51. PubMed ID: 24806546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
    Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
    Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes.
    Munk M; Memon AA; Goetze JP; Nielsen LB; Nexo E; Sorensen BS
    PLoS One; 2012; 7(7):e40243. PubMed ID: 22792252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
    Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM
    Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.